{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T03:16:15Z","timestamp":1782011775056,"version":"3.54.5"},"reference-count":17,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022739","name":"Institut Hospital del Mar d'Investigacions M\u00e8diques","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.esmoop.2024.103690","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T16:15:45Z","timestamp":1724948145000},"page":"103690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study"],"prefix":"10.1016","volume":"9","author":[{"given":"A.","family":"Rodriguez-Vida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.P.","family":"Valderrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Climent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Domenech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Perez-Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bonfill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Morales-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gonzalez-Billalabeitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Garcia-del-Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Maroto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Navarro-Gorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Juanpere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2328-3421","authenticated-orcid":false,"given":"J.","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.esmoop.2024.103690_bib1","first-page":"S1254","article-title":"LAB6 EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103690_bib2","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/jamaoncol.2019.0182","article-title":"Treatment of metastatic urothelial cancer in 2018","volume":"5","author":"Bellmunt","year":"2019","journal-title":"JAMA Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2024.103690_bib3","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \"unfit\" for Cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103690_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103690_bib5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","article-title":"Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial","volume":"52","author":"Dogliotti","year":"2007","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103690_bib6","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10122","key":"10.1016\/j.esmoop.2024.103690_bib7","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103690_bib8","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10064","key":"10.1016\/j.esmoop.2024.103690_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103690_bib10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.eururo.2017.08.022","article-title":"Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer","volume":"73","author":"Szabados","year":"2018","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103690_bib11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdv615","article-title":"Regulation of PD-L1: a novel role of pro-survival signalling in cancer","volume":"27","author":"Chen","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103690_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ"},{"issue":"13","key":"10.1016\/j.esmoop.2024.103690_bib13","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103690_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103690_bib15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10236","key":"10.1016\/j.esmoop.2024.103690_bib16","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.esmoop.2024.103690_bib17","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N\u00a0Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T19:35:22Z","timestamp":1727379322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924014595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2059702924014595"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103690","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103690"}}